Valuation: CSL Limited

Market Cap 41.37B 35.96B 33.47B 30.73B 58.04B 3,949B 58.93B 395B 155B 1,966B 155B 152B 6,593B P/E 2026 *
-46.3x
P/E 2027 * 28.8x
Enterprise Value 49.98B 43.45B 40.44B 37.13B 70.12B 4,771B 71.21B 477B 187B 2,375B 188B 184B 7,965B EV / Sales 2026 *
3.25x
EV / Sales 2027 * 3.16x
Free-Float
99.3%
Yield 2026 *
3.29%
Yield 2027 * 3.38%
1 day-3.28%
1 week+8.59%
Current month+12.03%
1 month+12.03%
3 months+1.14%
6 months-32.57%
Current year-25.63%
1 week 16.7
Extreme 16.7
18.3
1 month 16.3
Extreme 16.3
18.3
Current year 12.7
Extreme 12.7
43.4
1 year 12.7
Extreme 12.7
43.4
3 years 12.7
Extreme 12.7
47.5
5 years 12.7
Extreme 12.7
51
10 years 12.7
Extreme 12.7
52.5
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%+8.59% - - 42.95B
+0.37%+16.31%+39.88%+2.84% 75.12B
+2.72%-8.27%+20.23%+179.60% 47.63B
-2.75%+48.50%+48.50%+48.50% 49.48B
-1.52%+1.09%+59.69%-24.35% 30.72B
-5.38%+2.14%+60.49%+88.62% 24.93B
-3.17%+3.29%+88.94%-52.53% 22.98B
-1.59%-4.78%-11.93%+136.89% 19.56B
-0.42%+2.89%+74.55%+128.45% 17.19B
+2.87%-3.71%+71.14%+131.08% 16.06B
Average -1.10%+1.77%+50.16%+71.01% 33.74B
Weighted average by Cap. -0.43%+2.46%+45.89%+60.63%

Financials

2026 *2027 *
Net sales 15.38B 13.37B 12.44B 11.43B 21.58B 1,468B 21.91B 147B 57.57B 731B 57.76B 56.49B 2,451B 15.58B 13.55B 12.61B 11.58B 21.86B 1,488B 22.2B 149B 58.33B 741B 58.52B 57.24B 2,483B
Net income -967M -840M -782M -718M -1.36B -92.28B -1.38B -9.22B -3.62B -45.94B -3.63B -3.55B -154B 1.18B 1.03B 958M 880M 1.66B 113B 1.69B 11.3B 4.43B 56.3B 4.45B 4.35B 189B
Net Debt 8.61B 7.49B 6.97B 6.4B 12.08B 822B 12.27B 82.16B 32.24B 409B 32.35B 31.64B 1,373B 7.87B 6.84B 6.36B 5.84B 11.03B 751B 11.21B 75.02B 29.44B 374B 29.54B 28.89B 1,253B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change
26-07-31 17.70 -3.28%
26-07-30 €18.30 +1.67%
26-07-29 €18.00 +7.78%
26-07-28 €16.70 -1.18%
26-07-27 €16.90 +1.81%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
86.38USD
Average target price
97.43USD
Spread / Average Target
+12.79%

Quarterly revenue - Rate of surprise